This page contains brief information about lenalidomide and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Lenalidomide is approved to treat:
- Anemia caused by certain types of myelodysplastic syndromes. It is used in adults.
- Follicular lymphoma in adults who have already received other treatment. It is used with rituximab.
- Mantle cell lymphoma in adults whose disease recurred (came back) or got worse after two other treatments, including bortezomib.
- Marginal zone lymphoma in adults who have already received other treatment. It is used with rituximab.
- Multiple myeloma in adults. It is given with dexamethasone. It is also used alone as maintenance therapy in adults who received an autologous stem cell transplant.
Lenalidomide is only available as part of a special program called Revlimid REMS (Risk Evaluation and Mitigation Strategies).
Lenalidomide is also being studied in the treatment of other conditions and types of cancer.
More About Lenalidomide
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Lenalidomide - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Lenalidomide - Check for trials from NCI's list of cancer clinical trials now accepting patients.